Abstract: An ultrasonic device is provided for use on a biological tissue, and includes a base assembly on which a vibrator is mounted, and an ultrasonic probe. The base assembly includes an annular base having at least two pairs of abutment protrusions for abutting against the biological tissue, and an installation base coaxially disposed on and rotatable relative to the annular base between two test positions. The installation base has a through hold in which the ultrasonic probe is inserted.

Abstract: An ultrasonic device is provided for use on a biological tissue, and includes a base assembly on which a vibrator is mounted, and an ultrasonic probe. The base assembly includes an annular base having at least two pairs of abutment protrusions for abutting against the biological tissue, and an installation base coaxially disposed on and rotatable relative to the annular base between two test positions. The installation base has a through hold in which the ultrasonic probe is inserted.

Abstract: In some aspects, the invention provides a method of treating atherosclerosis in a subject. The method comprises administering to the subject an agent that increases the activity or level of a let-7 miRNA or an agent that decreases activity or level of a TGF? signaling polypeptide in an endothelial cell in the subject. In some embodiments, the subject is administered an additional agent comprising a therapeutically effective amount of rapamycin or any derivative thereof. In some embodiments, the agent is a let-7 miRNA. In some other aspects, the invention provides a pharmaceutical composition comprising a let-7 miRNA. In some embodiments, the let-7 miRNA is encapsulated in a nanoparticle formulated for selective delivery to an endothelial cell.

Abstract: The application discloses a data analysis system and a data analysis method. The data analysis system includes a data provider host and a data analysis host. The data provider host is configured to perform a stream cipher algorithm based on raw data to obtain first data. The data analysis host is configured to perform a data analysis based on the first data to obtain an analysis result. The data provider host or the data analysis host is further configured to perform a block cipher algorithm based on the analysis result to obtain second data, and send the second data to an external device. The data provider host is further configured to calculate an attribute-value correspondence between the raw data and the second data, and send the attribute-value correspondence to the external device.

Abstract: In some aspects, the invention provides a method of treating atherosclerosis in a subject. The method comprises administering to the subject an agent that increases the activity or level of a let-7 miRNA or an agent that decreases activity or level of a TGF? signaling polypeptide in an endothelial cell in the subject. In some embodiments, the subject is administered an additional agent comprising a therapeutically effective amount of rapamycin or any derivative thereof. In some embodiments, the agent is a let-7 miRNA. In some other aspects, the invention provides a pharmaceutical composition comprising a let-7 miRNA. In some embodiments, the let-7 miRNA is encapsulated in a nanoparticle formulated for selective delivery to an endothelial cell.

Abstract: A chemical vapor deposition process includes: performing a first-vapor deposition process to maintain a first temperature for a first time period; and performing a second-vapor deposition process, which includes: a temperature rising step, which makes the first temperature rise to a second temperature within a second time period; and a temperature dropping step, which makes the second temperature drop to a third temperature within a third time period.

Abstract: A measuring system for measuring elasticity of biological tissue includes a mobile device and a measuring apparatus including a conducting seat and a measuring device. The conducting seat is for detachable mounting of the mobile device therein, and is adapted to abut against the biological tissue for conducting vibrations produced by the mobile device to the biological tissue to cause the biological tissue to vibrate. The measuring device includes an ultrasonic transducer to emit an ultrasound signal to the biological tissue and an elasticity analyzer to analyze an ultrasound echo signal that results from reflection of the ultrasound signal by the biological tissue which is vibrating to obtain an elasticity data of the biological tissue.

Abstract: A measuring system for measuring elasticity of biological tissue includes a mobile device and a measuring apparatus including a conducting seat and a measuring device. The conducting seat is for detachable mounting of the mobile device therein, and is adapted to abut against the biological tissue for conducting vibrations produced by the mobile device to the biological tissue to cause the biological tissue to vibrate. The measuring device includes an ultrasonic transducer to emit an ultrasound signal to the biological tissue and an elasticity analyzer to analyze an ultrasound echo signal that results from reflection of the ultrasound signal by the biological tissue which is vibrating to obtain an elasticity data of the biological tissue.

Abstract: An artificial joint includes a first joint assembly and a second joint assembly. The first joint assembly is adapted to be connected to a first bone and has a first contacting surface, wherein the first contacting surface includes a first convex arc surface, a second convex arc surface, and a third convex arc surface. The second joint assembly is adapted to be connected to a second bone and has a second contacting surface, wherein the second contacting surface is in contact with the first contacting surface and includes a first concave arc surface, a second concave arc surface, and a third concave arc surface, and the first concave arc surface, the second concave arc surface, and the third concave arc surface respectively correspond to the first convex arc surface, the second convex arc surface, and the third convex arc surface.

Abstract: The application discloses a data analysis system and a data analysis method. The data analysis system includes a data provider host and a data analysis host. The data provider host is configured to perform a stream cipher algorithm based on raw data to obtain first data. The data analysis host is configured to perform a data analysis based on the first data to obtain an analysis result. The data provider host or the data analysis host is further configured to perform a block cipher algorithm based on the analysis result to obtain second data, and send the second data to an external device. The data provider host is further configured to calculate an attribute-value correspondence between the raw data and the second data, and send the attribute-value correspondence to the external device.

Abstract: A processing chamber gas detection system is provided, including a chamber, an exhaust pipe, a connection pipe, and a gas detector. The chamber is configured to perform a chemical vapor deposition (CVD) process. The exhaust pipe is connected to the chamber and the pumping unit, and the connecting pipe communicates with the exhaust pipe. The gas detector is disposed on the connecting pipe and configured to detect the oxygen content in the air from the chamber. When the air in the chamber is pumped out via the pumping unit and the air flows through the exhaust pipe and the connecting pipe, the gas detector detects whether oxygen is contained in the air or not.

Abstract: An artificial joint includes a first joint assembly and a second joint assembly. The first joint assembly is adapted to be connected to a first bone and has a first contacting surface, wherein the first contacting surface includes a first convex arc surface, a second convex arc surface, and a third convex arc surface. The second joint assembly is adapted to be connected to a second bone and has a second contacting surface, wherein the second contacting surface is in contact with the first contacting surface and includes a first concave arc surface, a second concave arc surface, and a third concave arc surface, and the first concave arc surface, the second concave arc surface, and the third concave arc surface respectively correspond to the first convex arc surface, the second convex arc surface, and the third convex arc surface.

Abstract: A touch display apparatus having a fan-out side is provided. The touch display apparatus includes a first substrate, a second substrate, a touch sensing element and a display element. The first and the second substrate have a first surface and a second inner surface, respectively. The second substrate is disposed opposite to the first substrate. The second inner surface faces the first inner surface. The second substrate has a convex part and a concave part on the fan-out side. The second inner surface has a second outer lead bonding region in the convex part. The first outer lead bonding region of the first substrate is unshielded by the second substrate through the concave part. The second outer lead bonding region of the second substrate is unshielded by the first substrate. The touch sensing element and the display element are packaged in between the first and the second substrates.

Abstract: A method for forming epitaxial material on base material includes forming a stress cap layer on a base layer of a first semiconductor material. Then, a stress is induced on the base layer, wherein the stress is a tensile stress or a compressive stress. The stress cap layer is removed. An epitaxial layer of a second semiconductor material is formed on the base layer, wherein the second semiconductor material is different from the first semiconductor material.

Abstract: In some aspects, the invention provides a method of treating atherosclerosis in a subject. The method comprises administering to the subject an agent that increases the activity or level of a let-7 miRNA or an agent that decreases activity or level of a TGF? signaling polypeptide in an endothelial cell in the subject. In some embodiments, the subject is administered an additional agent comprising a therapeutically effective amount of rapamycin or any derivative thereof. In some embodiments, the agent is a let-7 miRNA. In some other aspects, the invention provides a pharmaceutical composition comprising a let-7 miRNA. In some embodiments, the let-7 miRNA is encapsulated in a nanoparticle formulated for selective delivery to an endothelial cell.

Abstract: A processing chamber gas detection system is provided, including a chamber, an exhaust pipe, a connection pipe, and a gas detector. The chamber is configured to perform a chemical vapor deposition (CVD) process. The exhaust pipe is connected to the chamber and the pumping unit, and the connecting pipe communicates with the exhaust pipe. The gas detector is disposed on the connecting pipe and configured to detect the oxygen content in the air from the chamber. When the air in the chamber is pumped out via the pumping unit and the air flows through the exhaust pipe and the connecting pipe, the gas detector detects whether oxygen is contained in the air or not.

Abstract: Methods for treating or preventing neointima stenosis are disclosed. The methods generally involve the use of a TGF? inhibitor, a SMAD2 inhibitor, an FGF Receptor agonist, a Let-7 agonist, or a combination thereof, to inhibit endothelial-to-mesenchymal transition (Endo-MT) of vascular endothelial cells into smooth muscle cells (SMC) at sites of endothelial damage. The disclosed methods can therefore be used to prevent or inhibit neointimal stenosis or restenosis, e.g., after angioplasty, vascular graft, or stent. Also disclosed are methods for increasing the patency of biodegradable, synthetic vascular grafts using a composition that inhibits Endo-MT. A cell-free tissue engineered vascular graft (TEVG) produced by this method is also disclosed.

Abstract: A baby sling with two shoulder straps includes a flexible body, two shoulder straps, waist belt and two adjustment flaps. The waist belt is coupled to the bottom edge of the flexible body. First couplers are disposed at the waist belt and positioned proximate to the left and right ends of the bottom edge of the flexible body, respectively. The two adjustment flaps flank the flexible body, are positioned proximate to the waist belt, and each include a second coupler coupled to a corresponding one of the first couplers. The second couplers of the adjustment flaps are coupled to the first couplers of the waist belt, respectively. The coverage of the baby's thighs is adjusted according to the baby's body size to maximize the support the baby's body receives.

Abstract: A touch-sensing display panel including a display panel and a touch-sensing unit is provided. The touch-sensing unit includes a plurality of first sensing series and a plurality of second sensing series. The first sensing series are electrically insulated from one another. Each first sensing series includes first touch pads and first bridge lines. Two neighboring first touch pads disposed on a same first sensing series are electrically connected with each other through one of the first bridge lines. The second sensing series are electrically insulated from one another. Each second sensing series includes second touch pads and second bridge lines. Two neighboring second touch pads disposed on a same second sensing series are electrically connected with each other through two second bridge lines which are at least 140 micrometers apart. A touch-sensing substrate is also provided.

Abstract: Methods for treating or preventing neointima stenosis are disclosed. The methods generally involve the use of a TGF? inhibitor, a SMAD2 inhibitor, an FGF Receptor agonist, a Let-7 agonist, or a combination thereof, to inhibit endothelial-to-mesenchymal transition (Endo-MT) of vascular endothelial cells into smooth muscle cells (SMC) at sites of endothelial damage. The disclosed methods can therefore be used to prevent or inhibit neointimal stenosis or restenosis, e.g., after angioplasty, vascular graft, or stent. Also disclosed are methods for increasing the patency of biodegradable, synthetic vascular grafts using a composition that inhibits Endo-MT. A cell-free tissue engineered vascular graft (TEVG) produced by this method is also disclosed.